HUTCHMED (China) Limited Sponsored ADR

HCM Healthcare Drug Manufacturers Specialty & Generic

HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.

14.27 0.35 +2.51%
Market cap
$2.5B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
4/9
Altman Z
3.53
Beneish M
−1.20
Dividend safety
n/a

HUTCHMED (China) Limited Sponsored ADR (HCM) Revenue

Alert me on Revenue

HUTCHMED (China) Limited Sponsored ADR's revenue for fiscal 2025 was $548.5M, down 13.0% from $630.2M in fiscal 2024. Over the past ten years it has ranged from $178.2M (fiscal 2015) to $838.0M (fiscal 2023); the current reading is higher than 82% of that period. HUTCHMED (China) Limited Sponsored ADR ranks 5th of 74 Drug Manufacturers Specialty & Generic companies by revenue.

Revenue, annual

Embed this chart

Annual newest first

Period Revenue Change
FY2025 $548.5M (12.96%)
FY2024 $630.2M (24.80%)
FY2023 $838.0M 96.52%
FY2022 $426.4M 19.73%
FY2021 $356.1M 56.21%
FY2020 $228.0M 11.27%
FY2019 $204.9M (4.31%)
FY2018 $214.1M (11.23%)
FY2017 $241.2M 11.63%
FY2016 $216.1M 21.25%

Against its own ten years

Low $178.2M High $838.0M
Ten-year median $241.2M
Current reading's percentile 82

Revenue against peers

What Revenue is

Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.

Reported line item

The full definition of Revenue →

More on HCM